News In Brief: Cheap American Drugs Replaced; EMA, FDA Differ on Toansa; Apotex Warned; Cheaper Drug Recalls
This article was originally published in The Gold Sheet
Executive Summary
“Cheap China drugs” paradigm turned on its head; EMA disagrees with FDA on Ranbaxy site; Apotex API site fails FDA test; Drug tracing will mean cheaper recalls.
You may also be interested in...
Apotex Withdraws 31 ANDAs After Failing To Ensure Data Integrity At Two Indian Manufacturing Plants
Persistent data integrity and quality unit failures at two Apotex plants in Bangalore, India, led to wholesale US market withdrawals by the Canadian generic drug manufacturer.
Sagent Turns Generic Injectable Shortages Into Business Opportunity
The specialty generic manufacturer has a facility dedicated to producing shortage drugs, a seemingly endless commercial opportunity given the development, regulatory and reimbursement challenges in the sterile injectable space.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”